Onco-Rec. To predict cancer relapse, detect minories
Detection of potential tumor-initiating cells (TICs) in peripheral blood to anticipate the relapse in breast and colorectal cancer.
An algorithm based on the presence of different markers has been designed. These markers are present in tumor-initiating cell (TICs), which could be involved in cancer relapse . These cells are not totally remove in a conventional chemotherapy treatment. Our diagnostic technology is applicable to peripheral blood samples drawn with the usual procedures in the follow-up of patients. The sample is analyzed by flow cytometry techniques, which is included in common routines in hospitals, and at an accessible cost for its standardization. It has allowed us to anticipate the relapse, so if we detect these cells, we can predict that this process is going to happen with a sensibility and specificity higher to the conventional actual methods.
Onco-Rec is a combination of molecular markers expression, integrated as an algorithm, witch allow us the detection of tumour-initiating cells (TICs), considering the tumour heterogeneity.
TICs have a different behaviour with respect to the rest of the tumour cells and they can not be removed by a chemotherapy treatment. The population of TICs in peripheral blood through which they will travel great distances to produce metastasis, can easily be below the detection thresholds of conventional diagnostic methods. But unfortunately, they are the potential culprits of relapse in patients. Different markers (which are included in our algorithm) have been describe to phenotype these cells. With Onco-Rec, we can detect TICs with the usual procedures of the patient and the health personnel.
This algorithm makes it possible to reduce the price in the current market test and since it can be implemented in the routine practices of the hospital center, it will not be necessary for an expert in the technique to develop it, facilitating the daily management.
“The detection of tumor-initiatng cells, as a system to predict cancer relapse”
Biomedical research field
“The detection of TICs anticipate the relapse and metástasis, which causes the death of cáncer patients”
“Anticipation to relapse in almost two years in 80% of patients”
Technology Solution contact
Aina Catalina Mesquida Marcos; e: firstname.lastname@example.org
Carmen Ramírez-Castillejo; e: email@example.com
Área de Innovación, Comercialización y Creación de Empresas
Centro de Apoyo a la Innovación Tecnológica – UPM